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1Preeclampsia is a hypertensive disorder of pregnancy with an incompletely understood pathogenesis.1 Alteration in 
the expression of modulators of angiogenesis,2 inflammation,3 
and cytoprotective enzymes1 have gained momentum as key 
regulators in preeclampsia.
Current dogma suggests that inadequate placentation 
because of deficient trophoblastic invasion of the uterine spi-
ral arteries leads to placental hypoxia and release of antiangio-
genic factors.4–6 This may account for the increased maternal 
circulatory levels of soluble fms-like tyrosine kinase-1  (sFlt-1) 
and soluble endoglin (sEng), along with decreased placental 
growth factor (PlGF) in preeclamptic women.7–9
The pathogenesis of preeclampsia carries a significant mal-
adaptive immune component.3,10 This includes activation of 
T-cell and B-cell lymphocytes,11 maternal release of systemic 
cytokines [tumor necrosis factor (TNF)-α, interleukin  (IL)-6, 
IL-2],12–14 complement activation,15 an upregulation in the 
mRNA expression of monocyte chemoattractant protein-1,16 
and immunostaining for IL-6.17 The ensuing inflammatory 
environment contributes to an elevation in vasoconstrictor 
factor endothelin-1 (ET-1),18 endothelial dysfunction, and 
impaired endothelium–dependent relaxation.19
In preeclampsia, antiangiogenic and inflammatory media-
tors have been linked to endothelial activation and vaso-
spasm.20 Yet, it remains unknown whether the 2 systems 
operate in sequence, in concert, or in opposition to inflict 
endothelial damage and vasospasm. Recently, we showed that 
in preeclampsia increased maternal systemic inflammation 
does not correlate with increased levels of the antiangiogenic 
factors sFlt-1 and sEng.21 Although our study implies that the 
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2 pathways likely function independently, it does not exclude 
the possibility that the inflammatory stimulus impacts angio-
genesis or vice versa.
Of clinical relevance is the interaction between angiogenic 
and inflammatory humoral factors that could be responsible 
for the heterogeneous clinical and laboratory manifestations 
of preeclampsia. Angiogenic factors may play a role based 
on the observation that apheresis of sFlt-1 stabilizes maternal 
blood pressure and prolongs pregnancy for a limited period 
of time.22 However, preeclamptic women randomized to 
 anti-inflammatory dexamethasone do better in terms of oligu-
ria, blood pressure, platelet count, and liver enzyme status.23
Steroids given at doses aimed to enhance fetal lung matu-
rity are administered to preeclamptic women in anticipation 
of preterm delivery.24 It remains unknown how steroids at 
these doses alter the clinical course of preeclampsia and 
activity of the proinflammatory and antiangiogenic path-
ways. Our objective was to test the hypothesis that steroids 
modify the balance of proangiogenic and antiangiogenic 
factors, and that this alteration contributes to the patient’s 
evolving clinical state.
Subjects and Methods
Subjects
We analyzed maternal serum samples retrieved serially from 70 con-
secutive women with singleton pregnancies before and after steroid 
administration. We studied 45 hypertensive women with chronic 
hypertension (CHTN, gestational age [GA; median {interquartile 
range}: 30 {28–32}] weeks, n=6), severe preeclampsia (sPE; GA: 
30 [28–30] weeks, n=32), and superimposed preeclampsia (spPE; 
GA: 29 [27–30] weeks, n=7). All hypertensive women were admit-
ted for evaluation of preeclampsia or spPE, respectively. Maternal 
blood specimens from 25 normotensive consecutive women pregnant 
with singletons admitted with shortened cervix (<2.5 cm) served as 
controls (CRL, GA: 29 [25–30] weeks). All patients were enrolled 
prospectively and signed informed consent.
Methods
Detailed methods are given in the online-only Data Supplement.
Results
Patient Clinical Characteristics
Maternal demographic, clinical data at enrollment, and preg-
nancy outcome characteristics are presented in Table S1 in the 
online-only Data Supplement.
Clinical Parameters Before and After Steroids
The composite clinical severity score was calculated in 
24-hour increments, up to the point of delivery. At admission, 
as shown in Table S1 and displayed in Figure 1A, women with 
sPE had significantly higher clinical severity scores (P<0.001). 
Twenty-four hours after inpatient observation, the clinical sta-
tus improved and approached that of CRL patients. This time 
interval corresponded to the period after administration of 
the first dose of steroids. After 48 hours from initiation of the 
steroid course, the clinical severity score increased, reflect-
ing a worsening clinical state. The clinical deterioration often 
prompted delivery. For the spPE group, the change in the clin-
ical score was statistically significant during time in a pattern 
similar to sPE (Figure 1B). The clinical score of women with 
CHTN was significantly lower compared with women with 
sPE and spPE (Figure 1C, P>0.05). Scores improved tran-
siently for 24 hours after admission and first dose of steroids, 
and remained at the baseline level until delivery. Analysis of 
the pattern of change in the maternal blood pressure showed 
that, when compared with CRLs, only sPE and spPE women 
displayed a decrease in both systolic (Figure 1D–F) and dia-
stolic (Figure 1G–I) blood pressure values during the 72 hours 
after initiation of steroid treatment. A return to the baseline 
was seen before delivery.
Clinical Laboratory Parameters Before and 
After Steroids
Maternal laboratory parameters at the time of admission are 
presented in Table S2. The laboratory severity scores for sPE 
(Figure 2A) and spPE (Figure 2B) remained unchanged post-
steroids. However, the laboratory score of women with CHTN 
increased significantly at the time of delivery, which was weeks 
after the initial workup for spPE and administration of steroids.
Circulating Levels of Angiogenic Factors
Figure 3 demonstrates the progression of the levels of angio-
genic factors in all study groups, before and after steroid 
administration. In Table S3, we present the absolute values for 
sFlt-1, PlGF, ratio of sFlt-1/PlGF, sEng before and 24 hours 
after completion of steroids. Compared with CRLs and CHTN 
groups, sPE and spPE women had significant higher sFlt-1 
levels on admission and at all other study points (Figure 3A). 
Except for the spPE group, sFlt-1 levels increased signifi-
cantly during the study period. In multivariate analysis, this 
effect was dependent on GA (P=0.001), but not steroid admin-
istration (P>0.100).
The highest levels of maternal serum PlGF were seen in 
healthy CRLs (Figure 3B). There was no difference in the lev-
els of PlGF among CHTN, sPE, and spPE groups. The mater-
nal levels of PlGF remained unchanged for all groups but 
CRLs, where a significant increase in its concentration was 
detected. This effect was not dependent on steroid treatment 
(P>0.100). The ratio sFlt-1/PlGF was significantly higher in 
sPE and spPE (Figure 3C). The ratio remained unchanged with 
treatment, except for the sPE group where the ratio increased 
in a GA-dependent manner. Compared with CRL and CHTN 
groups, the sEng levels were significantly higher for both sPE 
and spPE groups (Figure 3D). The sEng concentrations were 
not affected by steroid treatment.
Circulating Levels of Proinflammatory Markers 
IL-6 and C-Reactive Protein
The maternal circulatory levels of IL-6 and C-reactive pro-
tein (CRP) before and after completion of the steroid course 
are presented in Table S3. Compared with CRLs, on admis-
sion, all hypertensive women demonstrated higher mater-
nal systemic circulatory IL-6 levels (Figure 4). In sPE, 
after admission and steroids, IL-6 levels remained low for 
up to 48 hours, indicating a diminished inflammatory state 
(Figure 4A). In this group, IL-6 levels rebounded after 48 
hours returning to admission levels. In multivariate analy-
sis, this effect was dependent on steroid administration 
(P<0.001) and not on GA (P>0.100). A similar pattern was 
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observed in spPE except that the rebound occurred earlier 
(Figure 4B). Compared with CRLs, CHTN women had 
significantly higher maternal IL-6 levels, which were unaf-
fected by steroid treatment (Figure 4C). At baseline, the lev-
els of CRP were significantly elevated in sPE (Figure 4D) 
and spPE (Figure 4E), but not in CHTN (Figure 4F). A 
decrease in the level of CRP was seen after steroids in both 
sPE and spPE women, reaching levels no different to CRLs 
at 48 hours after initiation of treatment.
Circulating Levels of Lymphocyte T and B-Cell 
Activation Markers
The maternal circulatory levels of sIL-2R and total IgG before 
and after completion of the steroid course are presented in 
Table S3. At baseline, the sIL-2R levels were elevated only 
in women with spPE and remained unaffected during the 
steroid treatment in the hypertensive groups (Figure 5A–5C). 
CRL women displayed significantly lower levels of sIL-2R 
48 hours after initiation of treatment although concentrations 
were increased in spPE both before and 48 hours after ste-
roids. Total IgG levels were not different among groups either 
initially or at any study point (Figure 5D–5F).
Circulating Levels of ET-1
The maternal blood ET-1 concentration before and after 
completion of the steroid course is presented in Table S3. 
Before steroid therapy, only women with sPE and spPE had 
significantly higher circulating levels of ET-1 (Figure 5G–I). 
In response to steroids, ET-1 levels increased and remained 
persistently elevated in sPE women. After steroid treatment, 
the maternal ET-1 circulatory concentrations remained unaf-
fected in spPE, CHTN, and CRL women.
F5
Figure 1. Temporal changes in clinical score of women with severe preeclampsia (sPE; A), superimposed preeclampsia (spPE; B), and 
chronic hypertension (CHTN; C), before and after steroids. Systolic blood pressure (SBP) of women with sPE (D), spPE (E), and CHTN 
(F), before and after steroids. Diastolic blood pressure (DBP) of women with sPE (G), spPE (H), and CHTN (I), before and after steroids. 
Error bars: standard error. Statistical analysis: 2-way repeated measures ANOVA and Holm–Sidak multiple comparisons. *P<0.05 vs 
control (CRL); #P<0.05 vs before steroids.
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Relationships Between Angiogenic, 
Inflammatory/Immune Factors, Endothelin, and 
Clinical Symptoms
In the sPE group, maternal symptoms after steroid adminis-
tration correlated significantly with IL-6 (r=0.432, P=0.019) 
but not CRP (r=0.094, P=0.624). There was no correlation 
between the change in clinical score and maternal levels of 
either angiogenic factors (sFlt-1: r=0.216, P=0.257; PlGF: 
r=0.097, P=0.615; sEng: r=−0.020, P=0.918) or lymphocyte 
activation markers (sIL-2R: r=0.076, P=0.696; IgG: r=0.299, 
P=0.116). The increase in serum ET-1 levels observed in sPE 
women after the first dose of steroids did not correlate with 
either the clinical score (r=−0.057, P=0.756) or with the indi-
vidual blood pressure levels (systolic: r=0.147, P=0.429; dia-
stolic: r=−0.189 P=0.301).
Discussion
The impact of antenatal glucocorticoids on the clinical mani-
festations of sPE remains a subject of debate. Data from initial 
observational studies have suggested that steroids are associ-
ated with a more rapid improvement in clinical and laboratory 
parameters in patients with HELLP syndrome.25,26 This effect 
seemed to be dose and steroid-type dependent.27 However, 
most of these initial studies were retrospective, small in size, 
and focused exclusively on HELLP. A 2010 Cochrane review 
found no differences maternal morbidity and mortality rates in 
women treated with corticosteroids.28
Herein, we evaluated the progression of maternal symp-
toms and laboratory parameters in women with sPE and their 
correlation with markers of inflammation, T-cell, and B-cell 
activation, endothelial cell activation and dysfunction, and 
Figure 3. Temporal changes in maternal serum angiogenic factors [soluble fms-like tyrosine kinase-1 (sFlt-1; A)], placental growth factor 
(PlGF; B), ratio sFLT-1/PlGF (C), and soluble Endoglin (sEng; D) of women with severe preeclampsia (sPE), superimposed preeclampsia 
(spPE), and chronic hypertension (CHTN) vs controls (CRL) before and after steroids. Error bars: standard error. Statistical analysis: 2-way 
repeated measures ANOVA and Holm–Sidak multiple comparisons. *P<0.05 vs control (CRL); #P<0.05 vs before steroids.
Figure 2. Temporal changes in the laboratory score of women with severe preeclampsia (sPE; A), superimposed preeclampsia (spPE; 
B), and chronic hypertension (CHTN; C), before and after steroids. Error bars: standard error. Statistical analysis: 2-way repeated 
measures ANOVA and Holm–Sidak multiple comparisons. *P<0.05 vs control (CRL); #P<0.05 vs before steroids.
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angiogenesis after steroid treatment. We focused our atten-
tion on the antepartum period because clinical and labora-
tory events occurring during this critical time dictate either 
delivery or expectancy. Betamethasone had no effect on 
improving the laboratory parameters used clinically to evalu-
ate the degree of preeclampsia severity and need for delivery. 
Interestingly, there was no significant effect on the platelet 
count. A steroid-type effect could be responsible for our 
observation. Woudstra et al28 reported a greater improvement 
in platelet counts in HELLP patients receiving dexametha-
sone than in those receiving betamethasone. Another possible 
explanation is that our study included patients with sPE and 
spPE and did not focus exclusively on HELLP. As postulated 
by Barrilleaux et al,29 although sPE and HELLP syndrome 
may share common pathophysiologic features, they are possi-
bly different clinical entities from the perspective of placental 
involvement, peripheral cytokine activation,30 and mecha-
nisms of cell activation and injury.31 The heterogeneity of the 
preeclampsia syndrome is also supported by data suggest-
ing that patients with HELLP syndrome have both an anti-
angiogenic state and a pronounced inflammatory response, 
although in preeclampsia without HELLP manifestations the 
antiangiogenic shift dominates.32 Nevertheless, our results 
established a significant, albeit transient, improvement in 
clinical manifestations of sPE and spPE. From this perspec-
tive, our data concur with previous studies that have found 
no substantial improvement in the long-term outcome of sPE 
women treated with steroids29 as improvement in the clinical 
symptoms of women with sPE and spPE in our study was 
only transitory and delivery occurred soon after treatment.
The clinical observation that sPE women improve their 
symptoms in a transient fashion led us to consider whether ste-
roids were responsible for this effect by modifying the levels 
of sFlt-1, PlGF, and sEng or their relative ratios.33 At least in 
doses used to induce fetal lung maturity, we found no impact 
on either antiangiogenic or proangiogenic factors. In contrast, 
the change in the severity of preeclampsia symptoms con-
curred with a steroid-induced alteration in the inflammatory 
pathway, as evidenced by decreased maternal circulatory IL-6. 
However, there is robust crosstalk between inflammation and 
angiogenesis.34 Therefore, we do not dismiss the prospect of a 
steroid dose-dependent effect on angiogenesis. Wallace et al35 
showed that, in patients with HELLP syndrome, dexametha-
sone was associated with improved clinical signs, laboratory 
values, and a decrease in circulating levels of IL-6, sFlt-1, 
and sEng. The Mississippi steroid protocol used high doses of 
dexamethasone and focused on the first 24-hour after steroid 
administration. Therefore, it is possible that in our study the 
smaller steroid doses used for induction of lung maturity do 
not exercise an effect discernible through the circulatory lev-
els of the investigated angiogenic factors. Inclusion in the data 
analysis of angiogenic factor levels from postpartum samples 
could have also significantly confounded the sFlt-1 and sEng 
results published by Wallace et al.35
In humans, prednisolone lowers the level of maternal IL-6, 
but not IL-1β, IL-10, and soluble IL-6R in HELLP syn-
drome.36 The results of this study, consistent with a temporary 
decrease in the maternal serum levels of the same cytokine, 
are provocative because IL-6 engages the IL-6 receptor, which 
is restricted to a few immune cell types such as neutrophils 
Figure 4. Temporal changes in the maternal serum interleukin-6 (IL-6) of women with severe preeclampsia (sPE; A), superimposed 
preeclampsia (spPE; B), and chronic hypertension (CHTN; C), before and after steroids. Error bars: standard error. Statistical analysis: 
2-way repeated measures ANOVA and Holm–Sidak multiple comparisons method. *P<0.05 vs control (CRL); #P<0.05 vs before steroids. AQ4
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and leukocytes.37 Neutrophil activation has been implicated 
in the pathophysiology of preeclampsia and requires binding 
and transmigration of neutrophils through the endothelium.38 
This effect is attained via interaction of vascular endothelial 
adhesion molecules and surface receptors on neutrophils and 
an increase in nuclear translocation of NF-kB and increased 
levels of IL-6.39 IL-6 stimulates CRP release by the liver.40 
The relationship between IL-6 and CRP seems to be mini-
mally impacted by glucocorticoids.40 We propose that, in sPE 
and spPE, steroids affect CRP levels indirectly via decreas-
ing maternal circulatory levels of IL-6. In vitro time course 
experiments support the idea that IL-6 induces the expression 
of CRP in a delayed fashion.40 This observation is consistent 
with our in vivo data and may explain why CRP remained low 
despite the rebound of IL-6. The role of adaptive immunity 
in preeclampsia has also been extensively reviewed.41 Many 
questions remain regarding the interaction between various 
cytokines and T-cell and B-cell lymphocytes in preeclamp-
sia. In our study, neither sIL-2R nor total IgG was impacted 
by antenatal steroid treatment. The clinical scores did not 
correlate with our markers of T-cell and B-cell activation. 
Consequently, we suggest that the transient improvement in 
the clinical manifestations of sPE is related to IL-6 in par-
ticular and possibly to other proinflammatory cytokines that 
remain to be discovered.
We found that, in sPE and spPE, the maternal circulatory 
levels of ET-1 are increased. Our findings that steroid treat-
ment was associated with an increase in the maternal serum 
concentration of ET-1 despite the overall decrease in blood 
pressure and IL-6 levels are novel. The association between 
preeclampsia and ET-1 is not easily interpretable in humans. 
For example, ET-1 is known to increase in response to 
Figure 5. Temporal changes in maternal serum soluble IL-2 receptor (sIL-2R) of women with severe preeclampsia (sPE; A), superimposed 
preeclampsia (spPE; B), and chronic hypertension (CHTN; C) and controls (CRL) before and after steroids. Maternal serum total 
immunoglobulin (IgG) of women with sPE (D), spPE (E), and CHTN (F) vs CRL women before and after steroids. Maternal serum 
endothelin-1 (ET-1) in women with sPE (G), spPE (H), and CHTN (I) vs CRL women before and after steroids. Error bars: standard error. 
Statistical analysis: 2-way repeated measures ANOVA and Holm–Sidak multiple comparisons. *P<0.05 vs control (CRL); #P<0.05 vs 
before steroids.
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hypercortisolism (ie, Cushing syndrome).42 In this condition, 
the changes in ET-1 concentrations vary independently of 
hypertension. This paradox was previously attributed to the 
complex pathogenesis of the syndrome and to the observa-
tion that circulating ET-1 may not reflect tissue or endothelial 
ET-1 levels.
Corticosteroids increase production of anti-inflammatory 
mediators that inhibit phospholipase-A2 activity and subse-
quently decrease prostaglandin production.43 Furthermore, 
betamethasone induces relaxation of blood vessels through a 
nitric oxide–mediated mechanism that could transitory com-
pensate for the vasoconstrictor effect of ET-1.44 Thus, we can 
speculate that steroids lead to a temporary stabilization of the 
vascular endothelium via a cytokine, prostaglandin, and nitric 
oxide–mediated mechanism. Collectively, all the above may 
temporize the vasospasm and thus transiently improve mater-
nal blood pressure and headache.
In conclusion, our findings suggest that systemic inflam-
mation contributes to the maternal clinical symptoms of pre-
eclampsia. However, relief of inflammation through the use of 
corticosteroids is unlikely to significantly impact the clinical 
progression of preeclampsia or of its antiangiogenic profile.
Perspectives
The impact of corticosteroids on the course of preeclampsia is 
not well established. Our findings demonstrate that the current 
doses and the type of steroids used clinically for induction of 
lung maturity do not alter the antiangiogenic profile in patients 
with preeclampsia. In contrast, steroid administration causes 
a transient decrease in IL-6, which coincided with a brief 
clinical improvement. Future clinical studies should focus on 
distinguishing the significance of systemic inflammation and 
antiangiogenic status in the pathogenesis of preeclampsia.
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What Is New?
•	Antenatal corticosteroids alter the inflammatory state in women with 
preeclampsia, and administration of steroids correlates with the tran-
sient improvement in the clinical course.
•	Steroids do not affect the antiangiogenic profile of women with pre-
eclampsia.
What Is Relevant?
•	The current study describes the impact of steroids on patients with pre-
eclampsia, a unique hypertensive disorder of pregnancy.
•	 Levels of circulating angiogenic factors in pregnancy are unlikely to be 
impacted by antenatal corticosteroids, which are frequently adminis-
tered to pregnant women to mature fetal lungs in anticipation of delivery.
•	Although both an increased proinflammatory state and an antiangiogenic 
state have been associated with preeclampsia, these 2 pathogenic path-
ways seem to vary independent of each other.
Summary
Antenatal corticosteroids seem to alter the inflammatory path-
way although minimally affecting levels of circulating angiogenic 
factors.
The reduction in inflammation may explain the transient im-
provement in the clinical manifestations of sPE.
Novelty and Significance
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